Corporate report

RPS Diagnostics test approved for sale in Europe, other countries
Sarasota-based RPS Diagnostics Inc. says its FebriDx test received a CE mark, a conformity marking that allows a product to be sold in the European Economic Area, clearing the way for the company to start selling it in the European Union and several other countries.

FebriDx is a rapid in-office test that uses a small finger-stick blood sample to differentiate a patient's immune response to a viral or a bacterial respiratory infection. Results are available to a clinician in as soon as 10 minutes.

“The FebriDx test will advance our goal to positively impact global health care by facilitating an earlier diagnosis, helping to reduce the spread of disease and encourage the judicious use of antibiotics,” Robert Sambursky, CEO and president of RPS, says in a press release.